Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2018-09-26 Capital/Financing Update
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Ethics Approval for BTX 1308 Psoriasis Patient Study Secured 2 pages 110.5KB
Capital/Financing Update Classification · 85% confidence The document is an ASX/Media Release dated 27 September 2018 announcing that Botanix Pharmaceuticals has received ethics approval to commence a Phase 1b psoriasis patient study for BTX 1308. It discusses clinical trial plans, study design, and expected timelines. There are no financial statements, earnings data, or detailed financial analysis. The content is an announcement of a clinical development milestone rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings. It is a corporate announcement related to clinical trial progress, which is best classified under Capital/Financing Update (CAP) as it relates to company development activities and progress updates that could impact capital markets. The document length is about 5,000 characters, and it is a full announcement, not a brief note or report publication announcement.
2018-09-26 English
Annual Report to shareholders 70 pages 733.0KB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT for the year ended 30 June 2018' and contains detailed sections typical of an annual report, including Directors' Report, Auditor's Independence Declaration, Consolidated Financial Statements, Notes to the Financial Statements, Directors' Declaration, Independent Auditor's Report, and Corporate Governance Statement. The content includes comprehensive financial data, management discussion, and corporate information for the full fiscal year ending June 30, 2018. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K).
2018-09-20 English
Appendix 4G 11 pages 116.6KB
Regulatory Filings
2018-09-20 English
Botanix presents at European Dermatology Conference 34 pages 1.2MB
Investor Presentation Classification · 95% confidence The document is an ASX/Media Release dated 13 September 2018 from Botanix Pharmaceuticals. It is a detailed presentation for the 27th European Academy of Dermatology and Venereology (EADV) Congress, providing updates on clinical programs, product pipelines, and investment highlights. The content includes clinical trial phases, product candidate details, and scientific explanations, typical of an investor presentation. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The document is lengthy (15,000 characters) and contains substantive information rather than just an announcement or summary. Therefore, the document fits the category of an Investor Presentation (IP).
2018-09-12 English
Pause in trading 1 page 112.3KB
Regulatory Filings Classification · 95% confidence The document is a short market release announcing a pause in trading of the company's securities. It is a brief regulatory announcement without financial data, report content, or detailed disclosures. It does not fit into categories like financial reports, management information, or capital updates. The best fit is Regulatory Filings (RNS) as a general regulatory announcement.
2018-09-11 English
Botanix BTX 1503 Clinical Trial Update 2 pages 131.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX/Media Release dated 12 September 2018 providing an update on the BTX 1503 Phase 2 clinical trial. It discusses the status of the clinical trial, patient testimony, trial sites, and expected data timing. There are no financial statements, regulatory certifications, or detailed financial results. The document is a corporate announcement about clinical trial progress and related corporate activities, not a financial report or regulatory filing. It is also relatively short (3713 characters) and serves as a news update rather than a formal report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2018-09-11 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.